Daniel Nava Rodrigues
Overview
Explore the profile of Daniel Nava Rodrigues including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
4856
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westaby D, Jimenez-Vacas J, Figueiredo I, Rekowski J, Pettinger C, Gurel B, et al.
J Clin Invest
. 2024 Sep;
134(18).
PMID: 39286979
The widespread use of potent androgen receptor signaling inhibitors (ARSIs) has led to an increasing emergence of AR-independent castration-resistant prostate cancer (CRPC), typically driven by loss of AR expression, lineage...
2.
Rescigno P, Porta N, Finneran L, Riisnaes R, Figueiredo I, Carreira S, et al.
Eur J Cancer
. 2024 May;
205:114103.
PMID: 38729054
Background: PTEN loss and aberrations in PI3K/AKT signaling kinases associate with poorer response to abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). In this study, we assessed antitumor activity...
3.
Neeb A, Figueiredo I, Bogdan D, Cato L, Stober J, Jimenez-Vacas J, et al.
Mol Cancer Ther
. 2024 Feb;
23(6):791-808.
PMID: 38412481
Therapies that abrogate persistent androgen receptor (AR) signaling in castration-resistant prostate cancer (CRPC) remain an unmet clinical need. The N-terminal domain of the AR that drives transcriptional activity in CRPC...
4.
Hedayat S, Cascione L, Cunningham D, Schirripa M, Lampis A, Hahne J, et al.
Clin Cancer Res
. 2024 Feb;
30(10):2140-2159.
PMID: 38376926
Purpose: The multi-kinase inhibitor (mKi) regorafenib has demonstrated efficacy in chemorefractory patients with metastatic colorectal cancer (mCRC). However, lack of predictive biomarkers and concerns over significant toxicities hamper the use...
5.
Neeb A, Figueiredo I, Gurel B, Nava Rodrigues D, Rekowski J, Riisnaes R, et al.
Lab Invest
. 2023 Aug;
103(11):100245.
PMID: 37652207
BCL-2-associated athanogene-1L (BAG-1L) is a critical co-regulator that binds to and enhances the transactivation function of the androgen receptor, leading to prostate cancer development and progression. Studies investigating the clinical...
6.
de Bono J, Harris J, Burm S, Vanderstichele A, Houtkamp M, Aarass S, et al.
Cancer Rep (Hoboken)
. 2023 Feb;
6(2):e1699.
PMID: 36806722
Background: Elevated tissue factor (TF) expression, although restricted in normal tissue, has been reported in multiple solid cancers, and expression has been associated with poor prognosis. This manuscript compares TF...
7.
Sowalsky A, Figueiredo I, Lis R, Coleman I, Gurel B, Bogdan D, et al.
Clin Cancer Res
. 2022 Jun;
28(16):3509-3525.
PMID: 35695870
Purpose: Therapies targeting the androgen receptor (AR) have improved the outcome for patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively active AR splice variant-7 (AR-V7) has shown clinical...
8.
Fenor de la Maza M, Chandran K, Rekowski J, Shui I, Gurel B, Cross E, et al.
Eur Urol Oncol
. 2022 May;
5(6):659-667.
PMID: 35491356
Background: Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease in which molecular stratification is needed to improve clinical outcomes. The identification of predictive biomarkers can have a major impact...
9.
Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, et al.
Cancer Discov
. 2021 May;
11(11):2812-2827.
PMID: 34045297
PARP inhibitors are approved for treating advanced prostate cancers (APC) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed TOPARP-B...
10.
Paschalis A, Welti J, Neeb A, Yuan W, Figueiredo I, Pereira R, et al.
Cancer Res
. 2021 Apr;
81(4):1087-1100.
PMID: 33822745
Endocrine resistance (EnR) in advanced prostate cancer is fatal. EnR can be mediated by androgen receptor (AR) splice variants, with AR splice variant 7 (AR-V7) arguably the most clinically important...